EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Live microbials to boost Anti-SARS-CoV-2 immunity clinical trial (Live BASIC trial): a triple-blind randomized controlled trial

Daniel B Horton, Rahul Ukey, Abhilasha Madhvi, Tracy Andrews, Veenat Parmar, Nancy Reilly, Sanna M Mäkelä, Jonathan Peterson, Leah Hustad, Gloriana Wong, Emily S Barrett, Natalie Bruiners und 10 weitere

Infection · 2026

DOI: 10.1007/s15010-025-02697-4 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Infection, 2026. Verfasst von Daniel B Horton und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. daniel.horton@rutgers.edu. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, COVID-19 Vaccines. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, National Institute of Allergy and Infectious Diseases, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

With waning immunity and vaccine hesitancy, the COVID-19 pandemic continues to pose risks. A live microbial consortium (OL-1) with bacteria containing potentially cross-reactive antigens (CRAGs) stimulates anti-SARS-CoV-2 immune responses in vitro/vivo. We evaluated OL-1’s efficacy in enhancing anti-SARS-CoV-2 immunity in unvaccinated, previously infected adults.

Methods

We conducted a pilot, parallel-group, triple-blind randomized controlled trial in 2021–2022 involving 52 generally healthy adults ages 18–60, unvaccinated against COVID-19, with SARS-CoV-2 infection ≥ 4 months prior. Participants received 21 days of either standard-dose OL-1, high-dose OL-1, or placebo. The primary outcome was change in plasma anti-SARS-CoV-2 IgG titers from baseline to Day 21. Secondary efficacy outcomes included changes through Day 42, interferon gamma (IFNg) release from stimulated peripheral blood mononuclear cells, and new SARS-CoV-2 infections. Safety was assessed through adverse events.

Results

Significant increases in plasma IgG levels were observed by Day 42 in the standard-dose OL-1 group ( n = 17) compared to placebo ( n = 18) ( p = 0.02). No significant changes were observed in the high-dose group ( n = 17). Marginal increases in IFNg release were observed in standard-dose recipients after stimulation with CD4+-specific CRAG and SARS-CoV-2 peptides and TLR7 ligands; only changes post-TLR7 ligand stimulation were significant. No new SARS-CoV-2 infections were detected. The most common adverse events overall were mild gastrointestinal symptoms; headaches were more frequent in OL-1 recipients.

Conclusion

The live microbial consortium OL-1 was well-tolerated and associated with slightly increased anti-SARS-CoV-2 IgG levels in previously infected, unvaccinated adults at standard, but not high, dosage. Further research should confirm these findings and their clinical implications in larger populations. This study was registered on ClinicalTrials.gov (NCT04847349) on April 14, 2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2COVID-19 VaccinesHumansAdultMaleFemaleMiddle AgedImmunoglobulin GYoung AdultAntibodies, ViralAdolescentPilot ProjectsInterferon-gammaLeukocytes, Mononuclear

Stichwörter der Autor:innen

COVID-19ProbioticsRandomized controlled trialSecondary prevention

Substanzen

Immunoglobulin GAntibodies, ViralInterferon-gammaCOVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. daniel.horton@rutgers.edu.
  • Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, 112 Paterson Street, New Brunswick, NJ, USA. daniel.horton@rutgers.edu.
  • Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA. daniel.horton@rutgers.edu.
  • Public Health Research Institute, Department of Medicine, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
  • Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA.
  • Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ, USA.

Förderung

  • NIEHS NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NCATS NIH HHS
  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • IFF Health & Biosciences
  • National Institute of Environmental Health Sciences
  • National Center for Advancing Translational Sciences

Zitieren

APA

Horton, D. B., Ukey, R., Madhvi, A., Andrews, T., Parmar, V., Reilly, N., Mäkelä, S. M., Peterson, J., Hustad, L., Wong, G., Barrett, E. S., Bruiners, N., Carson, J. L., Getz, K., Greenberg, P., Iizuka, A., Roy, J., Pastuszak, A. W., Lehtinen, M. J., …, & Gennaro, M. L. (2026). Live microbials to boost Anti-SARS-CoV-2 immunity clinical trial (Live BASIC trial): a triple-blind randomized controlled trial. Infection. https://doi.org/10.1007/s15010-025-02697-4

Vancouver

Horton DB, Ukey R, Madhvi A, Andrews T, Parmar V, Reilly N, et al. Live microbials to boost Anti-SARS-CoV-2 immunity clinical trial (Live BASIC trial): a triple-blind randomized controlled trial. Infection. 2026. doi:10.1007/s15010-025-02697-4

BibTeX
@article{Horton2026,
  author = {Horton, Daniel B and Ukey, Rahul and Madhvi, Abhilasha and Andrews, Tracy and Parmar, Veenat and Reilly, Nancy and Mäkelä, Sanna M and Peterson, Jonathan and Hustad, Leah and Wong, Gloriana and Barrett, Emily S and Bruiners, Natalie and Carson, Jeffrey L and Getz, Kylie and Greenberg, Patricia and Iizuka, Alicia and Roy, Jason and Pastuszak, Alexander W and Lehtinen, Markus J and Blaser, Martin J and Panettieri, Reynold A and Gennaro, Maria Laura},
  title = {Live microbials to boost Anti-SARS-CoV-2 immunity clinical trial (Live BASIC trial): a triple-blind randomized controlled trial},
  journal = {Infection},
  year = {2026},
  doi = {10.1007/s15010-025-02697-4}
}
Kostenlos starten →